Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Ipilimumab, and Oxaliplatin in Advanced NSCLC
NCT04043195Phase 2Active, not recruiting
- Start
- Aug 2019
- Primary completion
- Dec 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin in non-small cell lung cancer (NSCLC). Primary endpoint: Objective Response Rate at 4 months. Started Aug 2019; status: active, not recruiting.
02
Drugs
oxaliplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04043195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04043195.